Horizon Pharma plc



Isabel M., RAVICTI® Patient

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's fullyear 2018 net sales and adjusted EBITDA guidance, expected growth in net sales of certain medicines, estimated peak annual net sales of teprotumumab, if approved; expected financial performance in future periods; expected timing of clinical trials, including the Phase 3 clinical trial of teprotumumab; expected increases in investment in Horizon Pharma's rare disease medicine pipeline and the impact thereof; potential market opportunity for Horizon Pharma's medicines in approved and potential additional indications; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon Pharma's actual future financial and operating results may differ from its expectations or goals; Horizon Pharma's ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon Pharma's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates, such as teprotumumab, and existing medicines for new indications; risks related to acquisition integration and achieving projected benefits; risks associated with regulatory approvals; risks in the ability to recruit, train and retain gualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.




Horizon Pharma is a Rare Disease Focused Company Well-Positioned for Sustainable and Rapid Growth

- We excel at commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases
- Our **patients-first** culture fuels our drive to build a **pipeline of breakthrough medicines** and explore all potential uses for our **diverse and durable portfolio**
- Our uniquely strong in-house business development capability, along with strong cash generation and balance sheet, enable further additions to our portfolio of development-stage programs and commercial products





Our Strategy is to Drive Shareholder Value by Capitalizing on Our Defining Strengths







(1) Horizon Pharma estimate; for U.S. net sales only. (2) Investigator-initiated trials.

YOY: year-over-year. MIRROR: Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving KRYSTEXXA. MIRROR is scheduled to start enrollment in 4Q '18. RECIPE: REduCing Immunogenicity to PegloticasE. TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect.


We Have Purposefully and Rapidly Transitioned to a Rare Disease Medicines Company






(1) RAYOS is known as LODOTRA outside the United States. (2) VIMOVO was re-launched by Horizon Pharma sales force in January 2014. (3) PENNSAID 2% was re-launched by Horizon Pharma sales force in January 2015. (4) BUPHENYL is known as AMMONAPS outside the United States. (5) Horizon Pharma divested the marketing rights to PROCSYBI and QUINSAIR in Europe, the Middle East and Africa on June 23, 2017. Horizon Pharma retains marketing rights for the two medicines in the U.S., Canada, Latin America and Asia. QUINSAIR is not approved in the United States.

We Have Rapidly Evolved into a Company Focused on Rare **Disease Medicines**



Orphan and Rheumatology Segment is Generating Strong Net Sales Growth



Orphan and Rheumatology Net Sales



For us, it's personal

8

\$ in millions

Second-Quarter 2018 and Recent Company Highlights

- Orphan and rheumatology segment net sales increased 17 percent; 67 percent of total net sales
- Implemented **new Company operating structure**; reporting net sales and operating income for strategic growth business, the orphan and rheumatology segment, and the primary care segment
- **KRYSTEXXA**[®] net sales increased 53 percent; on track for full-year net sales growth of >65 percent
- Initiating **new KRYSTEXXA immunomodulation study** conducted by Horizon Pharma using methotrexate; enrollment scheduled to begin in 4Q '18
- **Teprotumumab Phase 3 trial has reached its target enrollment of 76 patients**, significantly ahead of schedule; remaining subjects in screening to randomize over next few weeks
- Continued building our **R&D** capabilities through **important leadership additions**
- Added two new RAVICTI patents, with two more expected in August, resulting in five new patents over 18-month period; settlement with Lupin with market entrance in 2026
- Awarded Number One Place to Work on FORTUNE's "Best Workplaces in Health Care & Biopharma" list; recognized as one of the 2018 "50 Companies That Care" by PEOPLE and Great Place to Work[®]



Second-Quarter 2018 Results

(\$ in millions, except for per share amounts and YOY percent change)	2Q 2018	2Q 2017	% Change
Net sales ⁽¹⁾	\$302.8	\$289.5	5
Net loss	(32.8)	(209.5)	84
Non-GAAP net income	80.5	68.3	18
Adjusted EBITDA	116.8	127.0	(8)
Net loss per share – diluted	\$(0.20)	\$(1.29)	84
Non-GAAP earnings per share – diluted	0.48	0.41	17

Excluding 2Q 2017 PROCYSBI and QUINSAIR EMEA net sales, YOY net sales growth was 6.3 percent⁽¹⁾

(1) On June 23, 2017, Horizon Pharma completed the divestiture of a European subsidiary that owned the marketing rights to PROCSYBI and QUINSAIR in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. PROCYSBI and QUINSAIR EMEA net sales in the second quarter of 2017 were \$4.5 million. Excluding those sales, growth would have been 6.3 percent. Horizon Pharma retains marketing rights for the two medicines in the United States, Canada, Latin America and Asia.

Note: Non-GAAP net income and adjusted EBITDA are non-GAAP measures; see reconciliation slides at the end of the presentation for a reconciliation of GAAP to non-GAAP measures. YOY: year-over-year.



For us, it's personal 10

Full-Year 2018 Guidance

- Confirming full-year 2018 net sales guidance
- Increasing full-year 2018 adjusted EBITDA guidance •

	New Guidance	Previous Guidance
Net Sales	\$1.170 to \$1.200 Billion	\$1.170 to \$1.200 Billion
Adjusted EBITDA	\$400 to \$420 Million	\$390 to \$415 Million

- Segment assumptions: •
 - Orphan and rheumatology segment net sales growth of >20 percent, including KRYSTEXXA net sales growth of >65 percent
 - Primary care segment net sales of >\$350 million —



Note: Adjusted EBITDA is a non-GAAP measure; see reconciliation slides at the end of the presentation for a reconciliation of GAAP to non-GAAP measures.




Our Strong Financial Position Supports Our Growth Strategy Cash and Cash Equivalents of \$710M at June 30, 2018

Cash and Debt as of June 30, 2018

(in millions)

Cash and cash equivalents	\$710
Senior secured term loans – due 2024	818
Senior notes – due 2023	475
Senior notes – due 2024	300
2.5% exchangeable senior notes – due 2022	400
Total principal amount of debt	\$1,993



Net debt to LTM adjusted EBITDA leverage ratio of 3.6 times at June 30, 2018, and estimated at 3.1 times based on full-year 2018 adjusted EBITDA guidance⁽¹⁾

(1) Adjusted EBITDA and net debt are non-GAAP measures; see reconciliation slides at the end of the presentation for a reconciliation of GAAP to non-GAAP measures. LTM: last 12 months ended June 30, 2018.



* Senior Secured Term Loans schedule includes 1 percent annual amortization (\$8.5M of principal) and reflects a mandatory prepayment of \$23.5M made in June 2018 that is applied 1) to prepay the next eight amortization payments from June 30, 2018; and 2) the remaining amortizations on a pro rata basis.

For us, it's personal 12

Horizon Pharma is Well-Positioned for Sustainable and Rapid Growth

- Durable base of rare disease medicines
- Multiple growth opportunities

High-Growth Opportunities



- **KRYSTEXXA**: estimated peak annual net sales of >\$750M⁽¹⁾
- Teprotumumab: estimated peak annual net sales of >\$750M⁽¹⁾




- Additional rheumatology candidates
- Expect to acquire developmentstage assets through businessdevelopment initiatives



KRYSTEXXA

Flagship Medicine with **Significant Growth Potential**





KRYSTEXXA Is a Key Growth Driver With Significant Untapped Opportunity

- KRYSTEXXA indicated for uncontrolled gout⁽¹⁾⁽²⁾, a rare disease
 - KRYSTEXXA is the first and only biologic for uncontrolled gout patients that rapidly reverses disease progression⁽³⁾
 - U.S. market
 - ~100,000 addressable uncontrolled gout patient population (rheumatology and nephrology)⁽⁴⁾
 - Growth drivers
 - Tapping new areas of opportunity through our nephrology expansion
 - Invest in and capitalize on expansion of commercial organization
 - Invest in education as well as patient and physician outreach, sharing robust safety and efficacy data from Phase 3 trials

- (2) See full prescribing information at www.KRYSTEXXA.com.
- (3) Source: Adapted from Klippel 2008. Edwards NL. Gout. A. Clinical features. In: Klippel JH, Stone JH, Crofford LJ, White PH, eds. Primer on the Rheumatic Diseases. 13th ed. New York: Springer; 2008:241-249.
 (4) Horizon Pharma estimate.





⁽¹⁾ Uncontrolled gout is defined as chronic gout refractory (unresponsive) to conventional therapies.

KRYSTEXXA is the Only Medicine for Uncontrolled Gout That Rapidly Reverses Disease Progression⁽¹⁾

Gout

- Most common form of inflammatory arthritis⁽²⁾
- Results in urate crystal deposits on joints, organs or tissues⁽³⁾

KRYSTEXXA

- 42% of patients had complete response defined as reduced serum uric acid⁽¹⁾⁽⁴⁾
- **45%** of KRYSTEXXA patients had complete resolution of tophi⁽⁵⁾

Before and After 5 Months of KRYSTEXXA






(1) Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and Tolerability of Pegloticase for theTreatment of Chronic Gout in Patients Refractory to Conventional Treatment: Two Randomized Controlled Trials. JAMA. 2011; 306(7):711-720. (2) Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the U.S. general population: the National Health and Nutrition Examination Survey 2007-2008. (3) Neogi 2011, Rees 2014; Schumacher HR. Wolters Kluwer Health. 2008; 1 (1):1-12; Eggebeen AT Amer Fam Physic. 2007; 76 (6):801-808. (4) Complete response defined as serum uric acid levels <6mg/DL and maintained for duration of therapy. (5) Baraf H, et al. Arthritis Res Ther: 2013; 15:R137.

Gout Is Often Associated with Multiple Negative Consequences

Patients with high uric acid levels have multiple comorbidities; gout patients have an average of four comorbidities


Gout Patients with Comorbidity (%)



Urate Burden: Adapted from So A, Thorens B. J Clin Invest. 2010;120(6):1791-1799.

in the body – bones and joints, as well as organs, such as the heart and kidney


Uric acid deposits can occur almost anywhere



KRYSTEXXA: Differentiated Mechanism of Action for **Uncontrolled Gout**

KRYSTEXXA: PEGylated uricase

- Unlike other gout medicines, ٠ KRYSTEXXA converts urate, the source of uric acid crystals, into a water-soluble substance, allantoin
- The body can rapidly and easily ٠ eliminate allantoin
- Current oral urate-lowering ٠ therapies target patients' sUA levels by addressing the over production or under excretion of uric acid



the kidney is excreted⁽¹⁾

allantoin filtered through the kidney is excreted⁽¹⁾⁽²⁾

Renal excretion of allantoin is up to 10x more efficient than excretion of uric acid⁽²⁾



(1) Terkeltaub R, Bushinsky DA, Becker MA. Arthritis Res Ther. 2006;8 (suppl 1):S4 (2) McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE. Pharmacogenet Genomics. 2014;24(9):464-476. sUA: serum uric acid.

The KRYSTEXXA Story Exemplifies Our Commercial Execution

 Under-resourced and poorly marketed prior to acquisition

We ACQUIRE under-appreciated medicines through our uniquely strong in-house business development capability >2x pre-acquisition net sales
 40% YOY vial growth FY '17

We then OPTIMIZE the growth trajectory of our acquired medicines through focused commercial execution

- 100K patient population⁽¹⁾
- Strategy to enhance response rate
- >65% FY '18 expected net sales growth⁽¹⁾
- >\$750M est. peak annual sales⁽¹⁾

Next, we MAXIMIZE the value of our medicines through new markets and collaborative research

2018+


2016

THORIZON

(1) Horizon Pharma estimate.YOY: year over year.

2017

Since Acquiring KRYSTEXXA, Average Vials Sold Per Day Has Increased ~125 Percent





(1) Typical seasonality 4Q to 1Q. YOY: year-over-year. Vials are shown on a shipping-day basis versus selling-day basis. * Representation of vials sold per day pre-acquisition by Horizon Pharma in January 2016; average was 36 vials sold per day.

For us, it's personal

²⁰

Nephrology Represents a Significant Opportunity For KRYSTEXXA

Clinical need:

- 25-50% of Chronic Kidney Disease (CKD) patients have gout⁽¹⁾
- Gout is more prevalent as CKD advances
- Nephrologists have a high sense of urgency to protect the kidney
- Conventional gout therapies place further burden on the kidneys and have significant dosing limitations in CKD patients⁽²⁾⁽³⁾
- (1) Nephrologists estimates; based on Horizon Pharma qualitative research.

(2) Gout and Hyperuricemia in Chronic Kidney Disease, National Kidney Foundation. 2015.
 (3) Rees F, Hui M, Doherty M. Nat Rev Rheumatol. 2014;10(5):271-283.

 (3) Rees F, Hui M, Donerty M. Nat Rev Rheumatol. 2014;10(5):271-283.
 (4) Yood RA, Ottery FD, Irish W, Wolfson M. Effect of Pegloticase on Renal Function in Patients with Chronic Kidney Disease: A Post Hoc Subgroup Analysis of 2 Randomized, Placebo-controlled, Phase 3 Clinical Trials. BMC Res Notes. 2014;7:54. doi:10.1186/1756-








KRYSTEXXA meets the need:

- Mechanism of action is a significant area of differentiation
- Tested and proven effective and safe for uncontrolled gout patients with CKD⁽⁴⁾
- CKD patients can be effectively treated without dose adjustment⁽⁴⁾

Many nephrologists are unaware of KRYSTEXXA

"You've given me something in a sea of nothing." – Nephrologist Comment, 2017 Blinded Market Research

Second-Quarter KRYSTEXXA Growth of 53 Percent Driven by Continued Strong YOY Vial Growth of Nearly 60 Percent



ORPHAN A Stable Base of Rare Disease **Growth Assets**





RAVICTI Increasing Penetration of the Diagnosed Patient Population

• Indicated for urea cycle disorders (UCDs)

- UCDs are rare and life-threatening genetic diseases resulting in body's inability to remove ammonia from the blood stream⁽¹⁾
- U.S. market
 - ~2,600 people with UCDs; ~1,000 diagnosed population⁽²⁾
- U.S. market share
 - ~52% of diagnosed patients
- Growth drivers
 - Increase awareness and diagnosis of UCDs
 - Drive conversion from older-generation nitrogen-scavengers to RAVICTI
 - Increase awareness of label expansion to position RAVICTI as first-line therapy



See full prescribing information at www.RAVICTI.com.
 Horizon Pharma estimate.



PROCYSBI

Driving Additional Uptake

- Indicated for nephropathic cystinosis (NC)
 - NC is a rare and life-threatening metabolic disorder⁽¹⁾
 - Without cysteamine-depleting treatment, high intracellular cystine concentrations can occur in virtually all organs and tissues, leading to irreversible cellular damage, progressive multi-organ failure and death
- U.S. market
 - ~500-600 diagnosed patients; ~400-450 diagnosed patients on cystine-depleting therapy⁽²⁾
- U.S. market share
 - ~55% of diagnosed patients
- Growth drivers
 - Drive conversion of patients from older-generation therapy
 - Drive uptake of diagnosed but untreated patients
 - Increase awareness of label expansion (>1 year) to position PROCYSBI as first line of therapy
 - Identify undiagnosed patients



See full prescribing information at www.PROCYSBI.com.
 Horizon Pharma estimate.



ACTIMMUNE Establishing Role of ACTIMMUNE in Broader Range of CGD Patients

- Indicated for chronic granulomatous disease (CGD)
 - CGD is a life-threatening immune disease that leads to recurrent severe bacterial and fungal infections⁽¹⁾
 - Patients have increased susceptibility to severe and recurrent bacterial and fungal infections, along with the formation and development of granulomas in most organs
- U.S. CGD market
 - ~1,600 people⁽²⁾
- Growth drivers
 - Increase awareness and diagnosis of CGD
 - Increase persistence of and adherence to treatment





See full prescribing information at www.ACTIMMUNE.com.
 Horizon Pharma estimate.



Our Pipeline

MEDICINE / CANDIDATE	DESCRIPTION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PHASE 3b / 4
● KRYSTEXXA®	 Immunomodulation Studies: MIRROR: KRYSTEXXA + methotrexate RECIPE*: KRYSTEXXA + mycophenolate mofetil TRIPLE*: KRYSTEXXA + azathioprine 					
RAYOS®	RIFLE trial: lupus*					••••
RAVICTI®	Label expansion: birth to 2 months					••••
 HZN-001 (teprotumumab)⁽¹⁾ 	 OPTIC trial: Phase 3 OPTIC-X trial: Phase 3 extension 					
HZN-003	 Optimized uricase and optimized PEGylation for uncontrolled gout 	•••••				
PASylation ⁽²⁾	 Optimized uricase and PASylation for uncontrolled gout 	•••••				
					• = 1	are disease

(1) Teprotumumab is a fully human monoclonal antibody (mAb) IGF-1R inhibitor for moderate-to-severe thyroid eye disease (TED). (2) Collaboration agreement. MIRROR: Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving KRYSTEXXA. MIRROR is scheduled to start enrollment in 4Q '18. RECIPE: REduCing Immunogenicity to PegloticasE. TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect. HORIZON RELETE: RAUGung miningenicity to regionade that the release prednisone) Inhibits Fatigue in Lupus Erythematosus. OPTIC: Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study.

28

* Investigator-initiated trial

Shao-Lee Lin, M.D., Ph.D., EVP, Head of R&D and CSO

Transforming our R&D Organization

Shao-Lee Lin, M.D., Ph.D., EVP, Head of R&D and CSO

- Joined Horizon Pharma in January 2018
- 20+ years as pharma executive, physician and scientist
- Immunologist, rheumatologist, allergist and internist
- Most recently at AbbVie, where she oversaw immunology, virology, neuroscience, general medicine and international development; prior to that at Gilead and Amgen
- Development programs under her leadership:

HUMIRA MAVYRET.

Cinbreit Achizenter (daclizumab)

New Key Leadership Roles: Bolstering Our R&D Capabilities

- Head of Development Sciences:
 - Leading critical development functions, including clinical pharmacology, statistics, toxicology and biomarkers
- Head of External Research and Development:
 - Leading R&D efforts in identifying, evaluating and executing transactions in partnership with commercial, business development and other key functions
- Orphan / Rheumatology Therapeutic Area Heads:
 - Leading the respective therapeutic areas' clinical development strategies and portfolio management

29

Dr. Lin is driving Horizon Pharma's next transformation in building a robust pipeline of medicines for sustainable long term growth

TEPROTUMUMAB

Meaningful Growth Opportunity Where Significant Unmet Need Exists



Teprotumumab: fully human monoclonal antibody inhibitor of IGF-IR

Teprotumumab Exemplifies the Next Phase of Our Strategy – Building a Pipeline for Sustainable Long-Term Growth

Teprotumumab

Pipeline Candidate Criteria


High unmet need with preference for rare diseases	 No FDA-approved therapies exist for thyroid eye disease Standard of care proven ineffective; safety concerns Surgery is invasive, complex and often ineffective
Viable market opportunity	 ✓ 15K-20K annual patient population⁽¹⁾ ✓ >\$750M U.S. peak sales potential⁽¹⁾
Compelling clinical trial data or proof of concept	 Impressive Phase 2 results published in <i>The New England Journal of Medicine</i> Phase 3 trial target enrollment completed ahead of schedule
Key regulatory designations	 U.S. Orphan; Fast-Track; Breakthrough Therapy
Compelling IP	 Potential exclusivity: 12-year biologic; 7-year orphan

Teprotumumab meets ALL criteria and has potential to be first therapy for moderate-to-severe thyroid eye disease (TED)

(1) Horizon Pharma estimate. Teprotumumab is an investigational candidate, and safety and efficacy have not been established.

Pathology of Thyroid Eye Disease (TED) and Mechanism of Action of Teprotumumab in TED

TED Pathology




- Rare, painful and debilitating autoimmune disease
- The body attacks its own orbital cells, overexpressing IGF-1R in orbital and immune cells, and forming a signaling complex with TSHR
- Leads to severe inflammation and expansion of tissue, muscle and fat cells behind the eye
- Causes proptosis (bulging of the eyes) and optic nerve compression



(1) Smith Terry J, Hegedus Laszlo., Graves' disease, The New England Journal of Medicine; 375 July 3, 2016, p. 1552-1565.; IGF-1R: insulin-like growth factor-1 receptor. TSHR: thyroid stimulating hormone receptor. IGF-1R: insulin-like growth factor-1 receptor. Teprotumumab is an investigational candidate, and safety and efficacy have not been established.

Teprotumumab MOA⁽¹⁾



- Fully human monoclonal antibody inhibitor of IGF-1R
- Binds to the IGF-1R/TSHR signaling complex
- Blocks autoantibodies and turns off IGF-1R/TSHR signaling at source of the disease
- Reduces inflammation and prevents excessive cell growth behind the eye

32

Moderate-to-Severe TED

- **Debilitating** autoimmune condition associated with Graves' disease
- Painful, sight-threatening, disfiguring and emotionally debilitating
- Begins as treatable (active) phase and moves to inactive phase

Orbital Inflammation & Swelling

Proptosis












How is TED Treated Today?

- No FDA-approved therapies
- Once TED reaches the inactive phase, long-term damage is done
- Surgery becomes only option⁽¹⁾
 - Complex with mixed results
 - ~3-5 surgeries per eye
 - While corrective for some, can result in permanent crosseyedness, double vision, lazy eye or blindness





(1) Surgical treatment can include decompression surgery, eyelid surgery and corrective vision surgery. Teprotumumab is an investigational candidate, and safety and efficacy have not been established.

Potential of Teprotumumab in TED

Active TED

Inactive TED

Patient not treated with teprotumumab





- No FDA approved treatments for active phase; off-label modalities do not affect the underlying disease
- Once TED progresses to the inactive phase, damage is irreversible and surgery is the only option



- Patient treated with teprotumumab: eight infusions over a 6-month period during active TED phase⁽¹⁾
- Teprotumumab "may result in a disease-modifying reduction in the volume of orbital fat, muscle or both"⁽²⁾
- Surgery may be able to be avoided



(1) This is based upon one patient's experience from the Phase 2 trial, which is not indicative of efficacy. Teprotumumab is an investigational candidate, and safety and efficacy have not been established. (2) The New England Journal of Medicine, 376:18, www.nejm.org, May 4, 2017.

Teprotumumab Clinical Development Phase 2 Trial Showed Unprecedented Clinical Efficacy in TED

- Double-blind, randomized, placebo-controlled with 88 patients
- Met its primary endpoint with statistically significant results
 - 69% of teprotumumab patients and 20% placebo patients were responders at Week 24 (p<0.001)
- Well-tolerated; 700-patient safety database exists from prior clinical program
- Results published in *The New England Journal of Medicine* in May 2017
- 71% of the teprotumumab patients achieved >2 mm reduction in proptosis (p<0.001)⁽¹⁾


The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE Teprotumumab for Thyroid-Associated Ophthalmopathy Terry J. Smith, M.D., George J. Kahaly, M.D., Ph.D., Daniel G. Ezra, M.D., James C. Fleming, M.D., Roger A. Dailey, M.D., Rosa A. Tang, M.D., Gerald J. Harris, M.D., Alessandro Antonelli, M.D., Mario Salvi, M.D., Robert A. Goldberg, M.D., James W. Gigantelli, M.D., Steven M. Couch, M.D., Erin M. Shriver, M.D., Brent R. Hayek, M.D., Eric M. Hink, M.D., Richard M. Woodward, Ph.D., Kathleen Gabriel, R.N., Guido Magni, M.D., Ph.D., and Raymond S. Douglas, M.D., Ph.D.

"In conclusion, a 24-week course of teprotumumab therapy provided clinical benefit in patients with active, moderate-to-severe thyroid-associated ophthalmopathy by reducing proptosis and the Clinical Activity Score and by improving the patients' quality of life."⁽²⁾

HORIZON

(1) Company data on file. (2) Smith Terry J, Hegedus Laszlo., Graves' disease, The New England Journal of Medicine; 375 July 3, 2016, p. 1552-1565. Clinical Activity Score (CAS): a 7-point scale that measures change in orbital inflammation and pain; a score of >3 indicates active TED. Teprotumumab is an investigational candidate, and safety and efficacy have not been established.

Teprotumumab Phase 3 Clinical Trial (OPTIC) Target Enrollment Completed, Well Ahead of Schedule



Primary endpoint at Week 24

- Proptosis responder rate defined as percentage of participants with <a>2 mm reduction in study eye without deterioration (<a>2 mm increase) in fellow eye
 - Proptosis selected as primary endpoint because it is objective, measurable and agreed upon by the FDA

Secondary endpoints at Week 24

- Percentage of participants with ≥2 point reduction in Clinical Activity Score (CAS) AND ≥2 mm reduction in proptosis (Phase 2 primary endpoint)
- Percentage of participants with CAS of 0 or 1
- Mean change in proptosis from baseline
- Mean change in QoL questionnaire overall score from baseline

(1) Assuming positive data and assuming priority review given fast-track designation.
 OPTIC: Treatment of Graves' Orbitopathy (TED) to reduce Proptosis with Teprotumumab Infusions in a randomized, placebo-controlled Clinical study.
 HORIZON BLA: Biologic License Application. Clinical Activity Score (CAS): a 7-point scale that measures change in orbital inflammation and pain; a score of >3 indicates active TED.
 For us, it's personal

37

We Expect Annual Addressable TED Patient Population of 15K to 20K⁽¹⁾ and U.S. Peak Net Sales Potential of >\$750M⁽²⁾

- U.S. incidence
 - 15K-20K patients eligible for treatment⁽¹⁾
 - Active phase lasts for 1 to 2 years
- Prescribing physicians
 - Endocrinologists, ophthalmologists and oculoplastic surgeons
 - Shift to primarily endocrinologists over time
- Commercial infrastructure
 - Orphan model
 - Leverage extensive experience
- Potential upside exists
 - Approval in additional geographies
 - Similar patient population in Europe



 (1) Company analysis of claims data and market research.
 (2) Horizon Pharma estimate.
 (3) Bahn RS, Current Insights into the Pathogenesis of Graves' Ophthalmopathy, Horn Metab Res; 47.
 (4) Based on 16:100,000 females, 2.9:100,000 males. Bartley GB. Trans Am Ophthalmol Soc. 1994;92:477-588. Teprotumumab is an investigational candidate, and safety and efficacy have not been established.



>3 Million Graves' Disease patients; 30% develop TED⁽³⁾

Annual U.S. Incidence of Active TED ~**30K**⁽⁴⁾

Annual U.S. Incidence Moderate-Severe Active TED 15K-20K⁽¹⁾

> Teprotumumab U.S. Net Sales Opportunity:

>\$750M⁽²⁾

Rheumatology Development Programs

Enhancing KRYSTEXXA and Our Leadership in Uncontrolled Gout



KRYSTEXXA immunomodulation trials

- MIRROR: Horizon Pharma-initiated trial expected to begin enrollment in 4Q '18
- RECIPE and TRIPLE: two investigator-initiated trials
- All three trials are evaluating immunomodulators familiar to rheumatologists

2 HZN-003 (optimized uricase and optimized PEGylation)

Potential subcutaneous dosing


PASylated uricase technology

- Evaluating PASylation technology as a biological alternative to synthetic PEGylation
- Potential subcutaneous dosing

To improve patient response rate and dosing convenience



MIRROR: Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving KRYSTEXXA. RECIPE: REduCing Immunogenicity to PegloticasE. TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect.



Uricase: uric-acid-specific enzyme


 PEGylation or PASylation: technology used to extend the uricase half-life

Progression of Potential Catalysts

2018	2019	2020 and beyond
 RAVICTI sNDA submission birth to two months KRYSTEXXA RECIPE trial start KRYSTEXXA TRIPLE trial immunomodulation arm start Teprotumumab Phase 3 target 	 Teprotumumab Phase 3 trial data Teprotumumab BLA submission 	 Teprotumumab BLA decision and launch⁽¹⁾ HZN-003 (optimized uricase and optimized PEGylation) Phase 1 trial start
 enrollment completed KRYSTEXXA MIRROR trial start RAVICTI sNDA approval PASylation lead candidate decision 		
✓ Milestone met		

(1) Assuming positive data and assuming priority review given fast-track designation.

Teprotumumab and HZN-003 are investigational candidates, and safety and efficacy have not been established.



RECIPE: REduCing Immunogenicity to PegloticasE. TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect. sNDA: Supplement New Drug Application.

HORIZON

ADDITIONAL PRODUCT INFORMATION



Primary Care Business Unit Provides Cash Flow to **Further Diversify**

- Managing the Primary Care business unit for cash flow to further diversify into ٠ rare disease medicines
- Four medicines: •
 - DUEXIS [®] and VIMOVO[®]: indicated for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA)
 - PENNSAID[®] 2%: indicated for treatment of OA of the knee⁽¹⁾
 - MIGERGOT[®]: indicated for treatment of migraines













Our Portfolio is Supported by Our Intellectual Property Expertise and Long-Life Protected Patents

Orphan and Rheumatology

RAVICTI° (gycerolphenylbutyrate)Oral Liquid	 9 OB listed patents extending to 2032; 2 additional patents scheduled to be issued in August 2018 Orphan Drug Exclusivity to 2020/2024 Settled Lupin litigation by granting a right to market no sooner than July 1, 2026
(1) PROCYSBI (csteardine bilatriate) delayed-release capaules	 5 OB listed patents extending to 2034 3 new patents issued in March 2018, extending to 2027 Orphan Drug Exclusivity: U.S. 2020/2022; E.U. 2023
	• 2 U.S. patents extending to 2022
(Quinsciir anadad turi el badbace	• 7 U.S. patents, 4 Canadian patents; not approved in U.S.
	 25 U.S. patents extending to 2030, including 1 new patent issued in 3Q '18 Biologic Exclusivity to 2022
RAYOS" (Prednisene) Delayed-release Tablets	 8 OB listed patents extending to 2028 Settled Actavis (first-filer) litigation with right to market Dec. 23, 2022

Primary Care

PENNSAID dicialezec sadion tepical salationi 2% win	 19 OB listed patents extending to 2030 Settled Teligent, Amneal, Paddock (Perrigo), Taro and Lupin litigations by granting a right to market no sooner than Oct. 17, 2027 In May 2017, U.S. District Court upheld '913 patent (extends to 2027) in case against Actavis
DUEXIS (buprofen and famotidine) Tablets 800 mg/26.6 mg	 6 OB listed patents extending to 2026 Settled Par (first-filer) litigation with right to market Jan. 1, 2023
VIMOVO [®] (naproxer /esomeprazide magnesium)	 14 OB listed patents (including esomeprazole patents) extending to 2031 11 OB listed patents (excluding esomeprazole patents) and 1 process patent In June 2017, U.S. District Court upheld both '285 patent (extends to 2022) and '907 patent (extends to 2023) in case against Dr. Reddy's Laboratories, Mylan and Lupin



(1) Horizon Pharma divested the marketing rights to PROCSYBI and QUINSAIR in Europe, the Middle East and Africa on June 23, 2017. Horizon Pharma retains marketing rights for the two medicines in the U.S., Canada, Latin America and Asia. QUINSAIR is not approved in the United States.

RECONCILIATIONS OF GAAP TO NON-GAAP MEASURES



Note Regarding Use of Non-GAAP Financial Measures

EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon Pharma as non-GAAP financial measures. Horizon Pharma provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax rate, non-GAAP operating cash flow and net debt, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon Pharma's performance, operations, expenses, profitability and cash flows. Adjustments to Horizon Pharma's GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich's ataxia, gain from divestiture, an upfront fee for a license of a patent, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, long-lived asset impairment charges, impacts of contingent royalty liability remeasurements and other noncash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon Pharma believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon Pharma's financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company's historical and expected 2018 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon Pharma's management uses for planning and forecasting purposes and measuring the Company's performance. For example, adjusted EBITDA is used by Horizon Pharma as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon Pharma has not provided a reconciliation of its full-year 2018 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon Pharma's stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon Pharma's actual net income (loss).



EBITDA and Adjusted EBITDA – Three and Six Months Ended June 30

(\$ in thousands)	1	hree Months Er	nded Ju	ne 30,	Six Months Ended June 30,			
		2018		2017		2018		2017
GAAP net loss	\$	(32,836)	\$	(209,536)	\$	(190,164)	\$	(300,106
Depreciation		1,551		1,755		3,104		3,561
Amortization, accretion and step-up:								
Intangible amortization expense		66,989		69,776		134,344		139,453
Accretion of royalty liabilities		14,797		12,735		29,515		25,694
Amortization of deferred revenue		-		(207)		-		(411
Inventory step-up expense		53		33,895		17,129		74,490
Interest expense, net (including amortization of								
debt discount and deferred financing costs)		31,030		31,608		61,484		63,591
Expense (benefit) for income taxes		3,962		(1,767)		3,596		(49,320
EBITDA	\$	85,546	\$	(61,741)	\$	59,008	\$	(43,048
Other non-GAAP adjustments:				<u> </u>				
Acquisition/divestiture-related costs		1,775		153,385		5,686		163,424
Restructuring and realignment costs		7,039		5,193		10,381		5,193
Litigation settlements		4,250		-		4,250		-
Impairment of long-lived assets		-		22,270		37,853		22,270
Remeasurement of royalties for medicines acquired through business combinations		-		-		(2,151)		(2,944
Share-based compensation		30,721		27,768		58,554		56,237
Charges relating to discontinuation of Friedreich's ataxia program		272		(3,103)		1,222		(3,103
Drug substance harmonization costs		475		745		1,279		5,044
Upfront and milestone payments related to license agreements		-		-		90		-
Fees related to term loan refinancing		15		(45)		42		4,098
Loss on debt extinguishment		-		-		-		533
Gain on divestiture		-		(5 <i>,</i> 856)		-		(5,856
Royalties for medicines acquired through business combinations		(13,259)		(11,622)		(25,780)		(22,939
Total of other non-GAAP adjustments		31,288		188,735		91,426		221,957
Adjusted EBITDA	\$	116,834	\$	126,994	\$	150,434	\$	178,909



EBITDA and Adjusted EBITDA – Full-Years 2017 and 2016

in thousands)		2017	2016		
		2017		2010	
BITDA and Adjusted EBITDA:					
GAAP net loss	\$	(410,526)	\$	(166,834	
Depreciation		6,631		4,962	
Amortization, accretion and inventory step-up:					
Intangible amortization expense		276,784		216,875	
Accretion of royalty liabilities		51,263		40,610	
Amortization of deferred revenue		(860)		(836	
Inventory step-up expense		119,151		71,13	
Interest expense, net (including amortization of					
debt discount and deferred financing costs)		126,523		86,610	
Expense Benefit for income taxes		(102,749)		(61,25	
EBITDA	\$	66,217	\$	191,279	
Other non-GAAP adjustments:					
Remeasurement of royalties for medicines acquired through business combinations		21,774		38	
Acquisition/divestiture-related costs		177,035		52,874	
Restructuring and realignment costs		4,883		-	
Gain on divestiture		(6,267)		-	
Loss on debt extinguishment		978		-	
Fees related to term loan refinancings		5,220		-	
Share-based compensation		121,553		114,144	
Litigation settlement		-		65,000	
Reversal of pre-acquisition reserve upon signing of contract		-		(6,90	
Impairment of in-process research and development		-		66,000	
Charges relating to discontinuation of the Friedreich's ataxia program		22,509		23,513	
Upfront and milestone payments related to license agreements		12,186		2,000	
Drug substance harmonization costs		10,651		-	
Royalties for medicines acquired through business combinations		(47,003)		(37,593	
Total of other non-GAAP adjustments		323,519		279,424	
Adjusted EBITDA	\$	389,736	\$	470,703	



GAAP to Non-GAAP Reconciliation *Operating Income*

	Т	hree Months E	nded Ju	ine 30,	Six Months Ended June 30,				
(\$ in thousands)		2018		2017		2018		2017	
GAAP Operating Income (Loss)	\$	1,814	\$	(185,667)	\$	(125,494)	\$	(291,050)	
Non-GAAP adjustments:									
Acquisition/divestiture-related costs		1,775		153,385		5,686		163,424	
Restructuring and realignment costs		7,039		5,193		10,381		5,193	
Litigation settlements		4,250		-		4,250		-	
Amortization, accretion and step-up:									
Intangible amortization expense		66,989		69,776		134,344		139,453	
Accretion of royalty liabilities		14,797		12,735		29,515		25,694	
Inventory step-up expense		53		33,895		17,129		74,490	
Impairment of long-lived assets		-		22,270		37,853		22,270	
Remeasurement of royalties for medicines acquired through business combinations		-		-		(2,151)		(2,944)	
Share-based compensation		30,721		27,768		58,554		56,237	
Depreciation		1,551		1,755		3,104		3,561	
Charges relating to discontinuation of Friedreich's ataxia program		272		(3,103)		1,222		(3,103)	
Drug substance harmonization costs		475		745		1,279		5,044	
Upfront and milestone payments related to license agreements		-		-		90		-	
Fees related to term loan refinancings		15		(45)		42		4,098	
Royalties for medicines acquired through business combinations		(13,259)		(11,622)		(25,780)		(22,939)	
Total of non-GAAP adjustments		114,678		312,752		275,518		470,478	
Non-GAAP Operating Income	\$	116,492	\$	127,085	\$	150,024	\$	179,428	
Orphan and Rheumatology Segment Operating Income		70,609		64,662		113,713		114,386	
Primary Care Segment Operating Income		45,883		62,423		36,311		65,042	
Total Segment Operating Income	\$	116,492	\$	127,085	\$	150,024	\$	179,428	
Amortization of deferred revenue		-		(207)		-		(411)	
Foreign exchange (loss) gain		(5)		151		(115)		(108)	
Other income, net		347		(35)		525		-	
Adjusted EBITDA	\$	116,834	\$	126,994	\$	150,434	\$	178,909	



GAAP to Non-GAAP Reconciliation Net Loss and Non-GAAP Net Income

	Three Months Ended June 30,					Six Months Ended June 30,				
(\$ in thousands)	2018			2017		2018		2017		
GAAP net loss	\$	(32,836)	\$	(209,536)	\$	(190,164)	\$	(300,106		
Non-GAAP adjustments:										
Acquisition/divestiture-related costs		1,775		153,385		5,686		163,424		
Restructuring and realignment costs		7,039		5,193		10,381		5,193		
Litigation settlements		4,250		-		4,250		-		
Amortization, accretion and step-up:										
Intangible amortization expense		66,989		69,776		134,344		139,453		
Accretion of royalty liabilities		14,797		12,735		29,515		25,694		
Amortization of debt discount and deferred financing costs		5,691		5,206		11,187		10,62		
Inventory step-up expense		53		33,895		17,129		74,49		
Impairment of long-lived assets		-		22,270		37,853		22,27		
Remeasurement of royalties for medicines acquired through business combinations		-		-		(2,151)		(2,94		
Share-based compensation		30,721		27,768		58,554		56,23		
Depreciation		1,551		1,755		3,104		3,56		
Gain on divestiture		-		(5,856)		-		(5,85		
Charges relating to discontinuation of Friedreich's ataxia program		272		(3,103)		1,222		(3,10		
Drug substance harmonization costs		475		745		1,279		5,04		
Upfront and milestone payments related to license agreements		-		-		90		-		
Fees related to term loan refinancings		15		(45)		42		4,09		
Loss on debt extinguishment		-		-		-		53		
Royalties for medicines acquired through business combinations		(13,259)		(11,622)		(25,780)		(22,93		
Total of pre-tax non-GAAP adjustments		120,369		312,102		286,705		475,78		
Income tax effect of pre-tax non-GAAP adjustments		(7,015)		(34,272)		24,668		(72,37		
Other non-GAAP income tax adjustments		-		-		(35,893)		-		
Total of non-GAAP adjustments		113,354		277,830		275,480		403,40		
Non-GAAP Net Income	\$	80,518	\$	68,294	\$	85,316	\$	103,30		



For us, it's personal

49

Loss per Share – Diluted and Non-GAAP Earnings per Share – Diluted

\$ in thousands, except for per share amounts)		Three Months Ended June 30,					Six Months Ended June 30,				
,		2018		2017		2018		2017			
Ion-GAAP Earnings Per Share:											
Weighted average ordinary shares - Basic		165,536,826		162,931,930		164,921,722		162,486,946			
Non-GAAP Earnings Per Share - Basic:											
GAAP loss per share - Basic	\$	(0.20)	\$	(1.29)	\$	(1.15)	\$	(1.85			
Non-GAAP adjustments		0.69		1.71		1.67		2.49			
Non-GAAP earnings per share - Basic	\$	0.49	\$	0.42	\$	0.52	\$	0.64			
Non-GAAP earnings per share - basic	<u> </u>										
Weighted average ordinary shares - Diluted	<u> </u>	165.536.826		162.931.930		164.921.722		162.486.94			
Weighted average ordinary shares - Diluted Weighted average ordinary shares - Basic	<u> </u>	165,536,826 3.820.913		162,931,930 2.033.141		164,921,722 3.678.249					
Weighted average ordinary shares - Diluted		165,536,826 3,820,913 169,357,739		162,931,930 2,033,141 164,965,071		164,921,722 3,678,249 168,599,971		2,499,409			
Weighted average ordinary shares - Diluted Weighted average ordinary shares - Basic Ordinary share equivalents Weighted average shares - Diluted		3,820,913		2,033,141		3,678,249		2,499,409			
Weighted average ordinary shares - Diluted Weighted average ordinary shares - Basic Ordinary share equivalents Weighted average shares - Diluted Non-GAAP Earnings Per Share - Diluted		3,820,913		2,033,141	 \$	3,678,249		2,499,409 164,986,35 5			
Weighted average ordinary shares - Diluted Weighted average ordinary shares - Basic Ordinary share equivalents Weighted average shares - Diluted Non-GAAP Earnings Per Share - Diluted GAAP loss per share - Diluted	\$	3,820,913 169,357,739	\$	2,033,141 164,965,071	\$	3,678,249 168,599,971	\$	2,499,409 164,986,355 (1.85			
Weighted average ordinary shares - Diluted Weighted average ordinary shares - Basic Ordinary share equivalents Weighted average shares - Diluted Non-GAAP Earnings Per Share - Diluted	\$	3,820,913 169,357,739 (0.20)	\$	2,033,141 164,965,071 (1.29)	\$	3,678,249 168,599,971 (1.15)	\$	162,486,946 2,499,409 164,986,355 (1.85 2.49 (0.01			

	As	of		
(\$ in thousands)	June 30, 2018	December 31, 2017		
Long-term debt-current portion	\$ -	\$ 10,625		
Long-term debt, net of current	1,562,013	1,576,646		
Exchangeable notes, net	323,105	314,384		
Total Debt	1,885,118	1,901,655		
Debt discount	97,737	108,054		
Deferred financing fees	10,171	11,041		
Total Principal Amount Debt	1,993,026	2,020,750		
Less: cash and cash equivalents	710,211	751,368		
Net Debt	\$ 1,282,815	\$ 1,269,382		



Horizon Pharma plc



Isabel M., RAVICTI® Patient